Pitfalls of using polymerase chain reaction–based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!
American Journal of Clinical Pathology · 2024
DOI: 10.1093/ajcp/aqad122 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Kritika Krishnamurthy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Montefiore Medical Center, Bronx, NY, US. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objectives
The BCR::ABL1 negative myeloproliferative neoplasms are sequentially tested for JAK2 p.V617F, followed by CALR exon 9 pathogenic variants. Historically, these variants were thought to be mutually exclusive. However, recent reports indicate coexisting JAK2 p.V617F and CALR exon 9 somatic variants.
Methods
Analysis of JAK2 p.V617F and CALR exon 9 variant was performed by polymerase chain reaction (PCR)–based assays. Subsequent testing was performed on the Genexus integrated sequencer (ThermoFisher) using the Oncomine myeloid assay GX v2.
Results
CALR exon 9 variants were positive in 3 cases, while 2 were positive for JAK2 p.V617F on PCR-based assays. Next-generation sequencing confirmed the JAK2 P.V617F status in all cases. CALR variants resulting in in-frame deletions were identified in 2 cases at a variant allele frequency of 52.16% and 50.91%, while the third case had an intronic CALR variant c.-48G>A at a variant allele frequency of 51.1%. Thus, CALR variants in all 3 cases were interpreted as potentially germline. Of the 228 cases that underwent JAK2 p.V617F and CALR cotesting in the past 2 years, only these 2 cases were positive for both JAK2 p.V617F and CALR exon 9 variants.
Conclusions
These cases highlight the importance of understanding the pitfalls of molecular techniques in current practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Montefiore Medical Center, Bronx, NY, US.
- Albert Einstein College of Medicine, Bronx, NY, US.
ORCID-Profile: Kritika Krishnamurthy, Yanhua Wang, D Yitzchak Goldstein
Zitieren
APA
Krishnamurthy, K., Chai, J., Wang, Y., Naeem, R., & Goldstein, D. Y. (2024). Pitfalls of using polymerase chain reaction–based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqad122
Vancouver
Krishnamurthy K, Chai J, Wang Y, Naeem R, Goldstein DY. Pitfalls of using polymerase chain reaction–based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqad122
BibTeX
@article{Krishnamurthy2024,
author = {Krishnamurthy, Kritika and Chai, Jiani and Wang, Yanhua and Naeem, Rizwan and Goldstein, D Yitzchak},
title = {Pitfalls of using polymerase chain reaction–based assays for JAK2 and CALR exon 9 variant testing in myeloproliferative neoplasms: Knowing when to go the extra mile!},
journal = {American Journal of Clinical Pathology},
year = {2024},
doi = {10.1093/ajcp/aqad122}
}
EUVIMED